Drugs / CB-5083
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02243917 | Oct 2014 → Aug 2017 | cancer | Cleave Biosciences, Inc. | Terminated | No outcome recorded |
| Phase 1 | NCT02223598 | Aug 2014 → Jul 2017 | refractory plasma cell neoplasm | Cleave Biosciences, Inc. | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CB-5083 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02223598 ↗ |
| Known as | CPD 71 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3747513 ↗ |
| Modality | Small molecule | — CHEMBL3747513 ↗ |
| Route | Oral | “CB-5083 will be administered orally, 4 days on and 3 days off, for 28 day cycles, as a single agent to subjects with lymphoid hematological malignancies” NCT02223598 ↗ |